MANKIND2023-01-012023-03-31 MANKIND2023-01-012023-03-31 MANKIND2023-01-012023-03-31in-bse-fin:OneOperatingExpenses01Member MANKIND2023-01-012023-03-31in-bse-fin:FourOperatingExpenses01Member MANKIND2023-03-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 543904 MANKIND NOTLISTED Mankind Pharma Limited Equity 2022-04-01 2023-03-31 2023-05-30 2023-05-22 INR Lakhs Yearly 17:05:00 18:45:00 2023-05-30 2023-05-30 true Cash Flow Indirect Declaration of unmodified opinion Single segment Pharmaceuticals 2023-01-01 2023-03-31 Audited Standalone 18721217000.00 424554000.00 19145771000.00 1639284000.00 4636201000.00 210039000.00 4310661000.00 8848000.00 672982000.00 4113421000.00 15591436000.00 3554335000.00 0.00 3554335000.00 808933000.00 -64478000.00 744455000.00 0.00 2809880000.00 0.00 0.00 0.00 0.00 2809880000.00 37017000.00 2846897000.00 2846897000.00 0.00 400588000.00 1 7.01 7.01 0.00 0.00 7.01 7.01 Explanatory notes to the Statement of Audited Standalone Financial Results for the quarter and year ended March 31, 2023: 1 The above audited standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards ( Ind AS ) as prescribed under section 133 of the Companies Act, 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 ( the regulations ). 2 These standalone financial results have been reviewed by the Audit Committee at its meeting held on May 30, 2023 and have been approved by Board of Directors at its meeting held on May 30, 2023. These results have been audited by the joint statutory auditors of the Company. 3 subsequent to the Balance sheet date, the Company has completed its Initial Public Offer (IPO) of 4,00,58,844 equity shares of face value INR 1 each at and issue price of INR 1,080 per share. The issue comprised of 100% offer for sale aggregating to INR 4,32,635.52 lacs. Pursuant to IPO, the equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on May 9, 2023. 4 The Company is engaged in manufacturing and trading of Pharmaceutical and consumer healthcare products. The Company has only one reportable segment 'Pharmaceuticals' and accordingly disclosures as per Ind AS 108 Operating Segments are not applicable. 5 The Company in the month of May 2021, filed a scheme of merger with National Company Law Tribunal (NCLT) for merging two of its wholly owned subsidiaries Lifestar Pharma Private Limited and Magnet Labs Private Limited with the Company. NCLT approval for the said merger was received by the Company vide order dated March 02, 2023. Pursuant to this, the Company has accounted the said scheme in accordance with Appendix C of Ind AS 103 Business Combinations and accordingly comparative period presented have been restated to give effect of the scheme in these standalone results. 6 During the current quarter, 10,46,512 options have been granted under the Mankind Employees Stock Option Plan 2022 to the eligible employees of the Company. No options have been vested and exercised during the quarter. 7 Subsequent to the year end in the month of May 2023, the Income Tax Department (‘the department’) conducted a search under section 132 of the Income Tax Act, 1961 at Company’s registered office, corporate office, few of its manufacturing locations and other premises and few of its group entities and residence of few of its employees/key managerial personnel. During the search proceedings, the Company has provided necessary information and responses to the department. Also, the department has taken certain documents, data backups and other information for further investigation. The business and operations of the Company continued without any disruptions and no demands have been raised on the Company as of date. Based on the foregoing and having regard to the matters of inquiry during the search proceedings stated above, management is of the view that no material adjustments are required to these standalone financial results in this regard. Single segment 2022-04-01 2023-03-31 Audited Standalone 81271532000.00 1627829000.00 82899361000.00 7110483000.00 18658232000.00 2678868000.00 17013785000.00 277481000.00 2695796000.00 18836350000.00 67270995000.00 15628366000.00 0.00 15628366000.00 2916358000.00 229428000.00 3145786000.00 0.00 12482580000.00 0.00 0.00 0.00 0.00 12482580000.00 -48589000.00 12433991000.00 12433991000.00 0.00 400588000.00 1 77438522000.00 31.16 31.16 0.00 0.00 31.16 31.16 Other expenses 4113421000.00 Other expenses 18836350000.00 14358093000.00 4378306000.00 53239000.00 65609000.00 16945217000.00 569536000.00 20407644000.00 0.00 338259000.00 20745903000.00 472052000.00 57587955000.00 10322152000.00 10614660000.00 4926415000.00 1341333000.00 210192000.00 983434000.00 552602000.00 18628636000.00 954178000.00 6186415000.00 36091381000.00 31878000.00 93711214000.00 400588000.00 77438522000.00 77839110000.00 77839110000.00 32261000.00 32261000.00 888713000.00 558543000.00 201725000.00 1681242000.00 14646000.00 8019647000.00 1796293000.00 9830586000.00 984161000.00 2945901000.00 430214000.00 14190862000.00 15872104000.00 93711214000.00 8 a) The figures for the quarter ended March 31, 2023 and March 31, 2022 are the balancing figures between the audited figures in respect of the full financial year ended March 31, 2023 and March 31, 2022 and audited year to date figures up to end of nine months of the current financial year and previous financial year respectively. b) The figures for the quarter ended December 31, 2022 are the balancing figures between the audited figures in respect of the year to date figures up to December 31, 2022 and the unaudited year-to-date figures up to September 30, 2022 as approved by the board of directors. 9 Other expenses includes impairment of non current assets being investment in subsidiaries and associate amounting to INR 4,550 lacs provided in year ended March 31, 2023 and other income includes INR 3,100 lacs being reversal of impairment allowance of financial assets on recovery of loan from a subsidiary company, having consequential impacts in quarter/period ended December 31, 2022 and March 31, 2022. (Also refer note 8 above). 10 During the current year, the Company has made following material investments: a. Equity shares in subsidiary companies amounting to INR 5,000 lacs in JPR Labs Private Limited and INR 1,409.38 lacs (including INR 400 lacs as share application money) in Lifestar Pharmaceuticals Private Limited. b. 0.01% Optionally Convertible Non-Cumulative Redeemable Preference Shares in subsidiary companies amounting to INR 3,300 lacs in Mankind Prime Labs Private Limited, INR 10,000 lacs in Mahananda Resorts & Spa Private Limited, INR 7,500 lacs in Mankind Life Sciences Private Limited, INR 3,050 lacs in Mankind Agritech Private Limited, INR 1,300 lacs in Mankind Consumer Healthcare Private Limited and INR 1,000 lacs in JPR Labs Private Limited. c. Capital contribu tion amounting to INR 4,894.80 lacs in Lifestar Pharma LLC. 11 During the previous year, the Company had acquired pharmaceutical formulation brands including their related trademarks and copyrights and other Intellectual Property Rights from Panacea Biotec Pharma Limited and Panacea Biotec Limited relating to their operations in India and Nepal. Accordingly, prior period numbers are not comparable to current period. 247327000.00 2344703000.00 -323062000.00 0.00 2902387000.00 0.00 0.00 -646376000.00 0.00 -1194086000.00 0.00 -695530000.00 0.00 2695796000.00 145000000.00 458248000.00 0.00 95830000.00 0.00 25879000.00 0.00 162199000.00 0.00 0.00 0.00 -582880000.00 0.00 0.00 -98886000.00 5212151000.00 20840517000.00 0.00 0.00 0.00 2850646000.00 0.00 17989871000.00 0.00 0.00 7122427000.00 3488597000.00 0.00 0.00 0.00 0.00 50640000.00 5483629000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 364161000.00 0.00 0.00 -350000000.00 3271000.00 0.00 752895000.00 0.00 0.00 5000.00 46976000.00 0.00 -8689425000.00 0.00 -10406140000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 5875897000.00 12700000000.00 20184000.00 3506000.00 0.00 256337000.00 0.00 0.00 -7104130000.00 479601000.00 0.00 479601000.00 861732000.00 1341333000.00 56899000.00 -74689000.00 18940000.00 -27369000.00 942000.00 1269000.00